CL · Q2 2025 Earnings
CautiousColgate-Palmolive
Reported August 1, 2025
30-second summary
Colgate cut the top of its FY25 organic sales growth guide, now expecting "the low end of 2% to 4%," and announced a $200-300M, three-year productivity restructuring — a defensive package, not a confident one. Q2 organic growth of 1.8% was carried by 2.0% pricing against -0.2% volume, with Latin America revenue down 4.8% and North America down 1.0%; Hill's (+3.8%) and Europe (+7.8%) did the work. Management's own language — pricing must drive growth "with lower levels of elasticity" — is the tell: the easy pricing lever is spent.
Headline numbers
EPS
Q2 FY2025
$0.92
Revenue
Q2 FY2025
$5.11B
+1.0% YoY
Gross margin
Q2 FY2025
60.1%
Operating margin
Q2 FY2025
21.1%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $5.11B | +1.0% |
| EPS | $0.92 | — |
| Gross margin | 60.1% | — |
| Operating margin | 21.1% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment performance
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Oral, Personal and Home Care | $3.954B | +0.3% |
| Pet Nutrition (Hill's) | $1.157B | +3.8% |
Platform metrics
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Organic Sales Growth | 1.8% |
| Global Toothpaste Market Share (YTD) | 41.1% |
| Global Manual Toothbrush Market Share (YTD) | 32.4% |
| Pricing Contribution | 2.0% |
| Volume Impact | -0.2% |
Profitability
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Gross Profit Margin | 60.1% |
| Operating Profit Margin | 21.1% |
| Base Business Operating Profit Margin | 21.3% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| North America | $1.027B | -1.0% |
| Latin America | $1.207B | -4.8% |
| Europe | $0.738B | +7.8% |
| Asia Pacific | $0.687B | +0.8% |
| Africa/Eurasia | $0.295B | +8.0% |
Management tone
The dominant shift this quarter is from preparing for volatility to executing through it with constrained tools. Management opened by noting that 2024 preparation "is paying off as the team continues to execute with resilience even as the environment remains difficult" — the second clause matters more than the first. This is not a company that thinks the operating environment is improving; it's a company arguing its planning is keeping it upright.
The most consequential tonal admission is on pricing elasticity. Management said outright: "our revenue growth management strategies need to drive additional pricing and mix with lower levels of elasticity as we look to improve organic sales growth in the second half of the year." Translated: consumers won't absorb price the way they did in 2022-2023, and yet pricing remains the primary growth lever (+2.0% price vs -0.2% volume this quarter). The H2 organic improvement story rests on RGM working harder against a less forgiving consumer — a setup that has a narrow margin for error.
The simultaneous announcement of a $200-300M, three-year productivity restructuring reframes the cost narrative. Management positioned it as "moving proactively to deliver incremental savings that can be levered to drive growth and create capabilities" — but proactive cost programs in mature CPG are almost never about growth; they're about funding the P&L when organic leverage falls short. The refusal to quantify headcount ("we're not going to go into detailed specifics here") is the most evasive moment of the call.
Tariffs are now a recurring carve-out rather than a contained line item. Guidance excludes US tariffs announced the night before the call, with management asserting no material impact "based on our preliminary analysis." That is a thinly-supported assurance, and it will be the first thing tested next quarter.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Dara Mosinian · Morgan Stanley
Details on restructuring program operational changes, savings payback versus charges timeline, and rationale for timing. Also requested perspective on US household products category slowdown and recovery outlook.
Restructuring is $200-300M charge over 3 years, designed to fund 2030 strategy investments in innovation, AI, data analytics, and omni-channel capabilities. Savings expected in similar range to prior program. US category slowdown attributed to cautious consumer; expect normalization by end of 2025 but near-term stability. North America business improved in quarter on volume; market share gains; promotional environment constructive.
Robert Ottenstein · Evercore ISI
Total toothpaste relaunch global assessment and Latin America market conditions, particularly Mexico and Brazil. Second half global program expectations.
Total relaunch launched in 75 markets; strong start in Latin America with good incremental share and growth. Asia and Europe also positive early signs. Latin America showing mixed signals: improvement in Mexico but deceleration in Brazil due to consumer cautiousness. Pricing taken in Q1 will benefit H2. Innovation investments continue across region; expect improvement as tariff noise recedes.
Kumil Garjawala · Jefferies
Hills business acceleration in flat pet food category. Whether driven by macro recovery or company initiatives.
Hills delivered mid-single digit organic growth across all hubs in flat category; ex-private label 5% organic growth. Volume and price well balanced (2% and 3% respectively). Therapeutic growing faster than wellness per strategy. Private label discontinued July; 80-90 bps impact in H2 vs prior year. Broad-based growth across wet, dry, treats, all species, prescription diet. Strong professional advocacy and new advertising campaign launched.
Chris Carey · Wells Fargo
Asia evolution including India softness and China JV performance. Balance between Colgate brand and Holly & Hazel business.
Asia softer than expected with weaker volume and pricing on Holly & Hazel in China. Colgate China performing exceptionally well with strong go-to-market execution and digital strategy. Holly & Hazel requires go-to-market adjustments, wholesaler channel fixes, and digital resource increases. India showing urban market softness but e-commerce up 500 bps in market share. Colgate Total and Total Core relaunches underway. Entry price point (10 rupee) being addressed. Optimistic on H2 improvements.
Steve Powers · Deutsche Bank
Prioritization of innovation within 2030 strategy—specifically whether focus is broad-based, premium, or better ROI alignment versus 2025 strategy execution.
2025 strategy innovation KPIs working well. Need to improve H2/H3 (breakthrough/transformational) innovation with increased resource allocation and longer development timelines. Some geographies not agile enough on H1 innovation; need better new news to trade. Geographies vary on execution quality; will allocate resources to improve H1 velocity and geographic consistency while building H2/H3 pipeline.
What to watch into next quarter
Whether Q3 organic growth accelerates above 2%. Management's H2 improvement thesis depends on Q1 Latin America pricing flow-through, Mexico recovery, and Colgate Total relaunch contribution. A second consecutive sub-2% organic print would force a guidance cut below the 2-4% range.
Hill's organic growth ex-private label. With private label production ceased in July and an ~80-90 bps quarterly drag in each of Q3 and Q4, the underlying ex-PL number is the real signal. Watch whether ex-PL stays at or above the 5% disclosed this quarter.
Tariff carve-out resolution. Guidance excludes the US tariffs announced 31 July. Either the next print confirms "no material impact" with disclosed quantification, or Colgate will need to reset gross margin and EPS guide.
Brazil organic trajectory and Latin America pricing realization. Latin America revenue -4.8% YoY is the largest geographic drag; Brazil deceleration is the cited culprit. Watch whether Latin America organic returns to positive in Q3.
Restructuring headcount disclosure. Management explicitly deferred specifics. The next call should quantify headcount actions and phasing of the $200-300M charge across 2025/2026/2027.
Volume vs price mix. -0.2% volume with +2.0% price is the elasticity ceiling that management itself flagged. If volume turns more negative while price holds, the H2 organic improvement story breaks.
Sources
- Colgate-Palmolive Q2 2025 Press Release Tables, filed via SEC EDGAR — https://www.sec.gov/Archives/edgar/data/21665/000002166525000040/q22025pressreleasetables.htm
- Colgate-Palmolive Q2 2025 earnings call commentary (management prepared remarks and Q&A)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.